Key Takeaways
- Morgan Stanley raised Rocket Lab’s bull‑case price target to $293, implying roughly 260 % upside from the current ~$81 share price and far above the Street consensus of $114.
- The upside hinges on three catalysts: an on‑time debut of the Neutron medium‑lift rocket (late 2026), successful closure of the $8 billion Iridium acquisition (mid‑2027) with visible earnings accretion, and conversion of a portion of the $151 billion Golden Dome defense opportunity into signed contracts.
- Rocket Lab already enjoys strong fundamentals: a $2.20 billion backlog, 63.5 % YoY revenue growth in Q1 FY26, and a record 16‑hour, 42‑minute responsive launch for the U.S. Space Force.
- Vertical integration through acquisitions (Iridium, Geost’s sensor business, Mynaric, Motiv) gives the company an end‑to‑end space‑platform capability and a recurring subscriber base of 2.5 million.
- Primary risks include Neptron schedule slips, continued net losses, and equity dilution from ATM offerings, which could blunt the upside potential.
Morgan Stanley’s recent note lifted Rocket Lab’s (NASDAQ:RKLB) bull‑case target to $293, a level that would require the stock to more than triple from its current price around $81.45. At that level, the implied market capitalization would be roughly $184 billion, up from today’s $47 billion. The bank maintains an Overweight rating with a $105 base case, but the bull case stands 157 % above the consensus Street target of $114.10, highlighting the extreme optionality analysts see in the company’s growth story.
The stock has been volatile, falling 17.94 % over the past week and 24.23 % over the past month as the broader space sector sold off after SpaceX’s June 2026 IPO. Despite the pullback, RKLB remains up 19.57 % year‑to‑date, 114.53 % over the last twelve months, and an astonishing 620.92 % over five years. The share price sits about 46 % below its 52‑week high of $151, marking the fourth drawdown of 40 % or more during its climb from under $4 per share.
Morgan Stanley’s bullish outlook rests on three pillars. First, the Neutron rocket—targeted for debut later in 2026—promises to unlock medium‑lift revenue streams and enable layered awards such as the Space Based Interceptor program under the Department of Defense’s Golden Dome initiative. A clean, on‑time launch with reusable recovery is essential; any slip would add‑on to the upside case.
Second, the $8 billion Iridium acquisition announced June 29 provides a massive backlog and a platform for recurring revenue. Morgan Stanley expects the deal to close on schedule in mid‑2027 and to contribute visible earnings accretion, reinforcing Rocket Lab’s transition from a launch‑services provider to an integrated space‑systems company. The acquisition adds roughly 2.5 million recurring subscribers and expands the firm’s sensor, communications, and propulsion capabilities through complementary purchases of Geost’s sensor business, Mynaric (laser communications), and Motiv (electric propulsion).
Third, Rocket Lab’s existing backlog already offers strong visibility: $2.20 billion in contracted work, over 70 missions, and the $816 million Space Development Agency (SDA) contract. This backlog provides multi‑year revenue certainty in a sector that often suffers from lumpy, project‑based income. The bank also highlights the company’s Q1 FY26 performance—revenue of $200.35 million, up 63.5 % YoY—and a record 16‑hour, 42‑minute responsive launch for the U.S. Space Force VICTUS HAZE mission as evidence of operational execution.
To reach the $293 target, Rocket Lab must convert a portion of the $151 billion Golden Dome defense opportunity into signed contracts, alongside the Iridium closing and Neutron debut. The implied market cap at $293 presumes that these catalysts materialize without significant setbacks. The primary downside risk remains Neptron schedule slippage, which could coincide with continued net losses and further equity dilution from ATM offerings, dampening investor sentiment.
In summary, Morgan Stanley’s aggressive bull case reflects confidence that Rocket Lab’s vertical integration, expanding backlog, and defense‑sector exposure can drive exponential growth—provided the company executes on its near‑term milestones. Investors should weigh the substantial upside against the execution risks inherent in developing a new launch vehicle and integrating a multibillion‑dollar acquisition.